ATE390442T1 - Mischung von peptiden aus den proteinen c und ns3 des hepatitis c-virus, und deren verwendung - Google Patents
Mischung von peptiden aus den proteinen c und ns3 des hepatitis c-virus, und deren verwendungInfo
- Publication number
- ATE390442T1 ATE390442T1 AT03769526T AT03769526T ATE390442T1 AT E390442 T1 ATE390442 T1 AT E390442T1 AT 03769526 T AT03769526 T AT 03769526T AT 03769526 T AT03769526 T AT 03769526T AT E390442 T1 ATE390442 T1 AT E390442T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- hcv
- specific
- hepatitis
- virus
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 2
- 101800004937 Protein C Proteins 0.000 abstract 1
- 101800001700 Saposin-D Proteins 0.000 abstract 1
- 102400000827 Saposin-D Human genes 0.000 abstract 1
- 230000027455 binding Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229960000856 protein c Drugs 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0209874A FR2843115B1 (fr) | 2002-08-02 | 2002-08-02 | Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE390442T1 true ATE390442T1 (de) | 2008-04-15 |
Family
ID=30129652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03769526T ATE390442T1 (de) | 2002-08-02 | 2003-08-01 | Mischung von peptiden aus den proteinen c und ns3 des hepatitis c-virus, und deren verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060110401A1 (de) |
| EP (1) | EP1527089B1 (de) |
| AT (1) | ATE390442T1 (de) |
| AU (1) | AU2003278213A1 (de) |
| CA (1) | CA2495456C (de) |
| DE (1) | DE60319990T2 (de) |
| FR (1) | FR2843115B1 (de) |
| WO (1) | WO2004014936A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2830940B1 (fr) | 2001-10-17 | 2007-06-15 | Commissariat Energie Atomique | Procede de selection de ligands d'hla-dp4 et ses applications |
| WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
| WO2004024182A2 (en) | 2002-09-13 | 2004-03-25 | Intercell Ag | Method for isolating hepatitis c virus peptides |
| US7704514B2 (en) | 2003-03-24 | 2010-04-27 | Intercell Ag | Vaccines |
| ATE489967T1 (de) * | 2003-07-11 | 2010-12-15 | Intercell Ag | Hcv-vakzin |
| JP2009018990A (ja) * | 2005-10-25 | 2009-01-29 | Univ Kurume | Ｃ型肝炎ウイルス由来ペプチド |
| FR3008099B1 (fr) | 2013-07-05 | 2020-08-07 | Commissariat Energie Atomique | Peptides immunogenes de l'antigene tumoral cycline b1 |
| CN108219002B (zh) * | 2018-01-22 | 2021-05-14 | 三诺生物传感股份有限公司 | 一种重组的c肽免疫原及其应用 |
| EP4069714A4 (de) * | 2019-12-06 | 2024-02-21 | Cooke Aquaculture Inc. | Peptide zur glucoseregulierung |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6692751B1 (en) * | 1988-05-06 | 2004-02-17 | New York Blood Center | Methods and systems for producing recombinant viral antigens |
| EP0754193B1 (de) * | 1994-04-08 | 2000-06-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Peptid aus dem inneren des hepatitis-c-virus brauchbar für die stimulation cytotoxischer t-lymphocyten und die diagnose des hcv-kontaktes |
| WO1996003423A1 (de) * | 1994-07-25 | 1996-02-08 | Boehringer Mannheim Gmbh | Hapten-markierte peptide |
| US6902743B1 (en) * | 1995-05-22 | 2005-06-07 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix |
| US6413517B1 (en) * | 1997-01-23 | 2002-07-02 | Epimmune, Inc. | Identification of broadly reactive DR restricted epitopes |
| US20030180284A1 (en) * | 1998-11-05 | 2003-09-25 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes |
| GB0026094D0 (en) * | 2000-10-25 | 2000-12-13 | Imp College Innovations Ltd | Methods |
-
2002
- 2002-08-02 FR FR0209874A patent/FR2843115B1/fr not_active Expired - Fee Related
-
2003
- 2003-08-01 DE DE60319990T patent/DE60319990T2/de not_active Expired - Lifetime
- 2003-08-01 AT AT03769526T patent/ATE390442T1/de not_active IP Right Cessation
- 2003-08-01 EP EP03769526A patent/EP1527089B1/de not_active Expired - Lifetime
- 2003-08-01 AU AU2003278213A patent/AU2003278213A1/en not_active Abandoned
- 2003-08-01 US US10/522,992 patent/US20060110401A1/en not_active Abandoned
- 2003-08-01 WO PCT/FR2003/002446 patent/WO2004014936A2/fr not_active Ceased
- 2003-08-01 CA CA2495456A patent/CA2495456C/fr not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1527089A2 (de) | 2005-05-04 |
| DE60319990D1 (de) | 2008-05-08 |
| AU2003278213A1 (en) | 2004-02-25 |
| CA2495456C (fr) | 2013-10-01 |
| DE60319990T2 (de) | 2009-04-09 |
| AU2003278213A8 (en) | 2004-02-25 |
| US20060110401A1 (en) | 2006-05-25 |
| WO2004014936A2 (fr) | 2004-02-19 |
| FR2843115B1 (fr) | 2007-11-09 |
| WO2004014936A3 (fr) | 2004-07-22 |
| CA2495456A1 (fr) | 2004-02-19 |
| EP1527089B1 (de) | 2008-03-26 |
| FR2843115A1 (fr) | 2004-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feldman et al. | Model of alpha 2-macroglobulin structure and function. | |
| ATE318309T1 (de) | Hcv-spezifische peptide, mittel dazu und ihre verwendung | |
| IL128826A0 (en) | A crystallizable composition comprising a hepatitis C virus NS3 like polypeptide complexed with a NS4 a-like peptide | |
| DE69029092D1 (de) | Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C-Virus | |
| EP2110385A8 (de) | Stabilisierte Faktor VIII mit manipulierten Disulfid-Bindungen | |
| ES2310701T3 (es) | Metodos para mejorar la conformacion de proteinas por medio de agentes reductores. | |
| ATE390442T1 (de) | Mischung von peptiden aus den proteinen c und ns3 des hepatitis c-virus, und deren verwendung | |
| RU94024561A (ru) | Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка | |
| WO2003012050A3 (en) | Mitochondrial genome replenishment | |
| Benjamin et al. | Heterogeneity in interleukin (IL)-1 receptors expressed on human B cell lines. Differences in the molecular properties of IL-1 alpha and IL-1 beta binding sites. | |
| CY1107431T1 (el) | Σωματιδια για γoνιδιακη θεραπεια | |
| JP2008508863A5 (de) | ||
| Kuwabara et al. | Mapping of the minimal domain encoding a conformational epitope by λ phage surface display: factor VIII inhibitor antibodies from haemophilia A patients | |
| AP2368A (en) | Novel expression vectors and uses thereof. | |
| DE60232155D1 (de) | Humaner rekombinanter antikörper gegen das hepatitis c (hcv) nichtstrukturelles ns3 protein, nukleinsäure und deren verwendungen | |
| Mattsson et al. | Antibodies to recombinant and synthetic peptides derived from the hepatitis C virus genome in long-term-studied patients with posttransfusion hepatitis C | |
| Anderson et al. | Comparison of two second‐generation anti‐hepatitis C virus ELISA on 21431 US blood donor samples | |
| Guastafierro et al. | Biclonal gammopathy and platelet antibodies in a patient with chronic hepatitis C virus infection and mixed cryoglobulinemia | |
| Mc Ginley | The Role of Cellular Compartments, Host Factors and the Viral Capsid in Hepatitis B Virus Entry | |
| Dobre et al. | Binding of cytophilic rabbit IgG to homologous hepatocytes | |
| ATE338061T1 (de) | Synthetische peptide die immunoreaktivität gegen den virus von hepatitis a zeigen | |
| So et al. | A Novel Protein to Bind RCV Core Protein: The Carboxyl Terminus-Truncated Core $ _ {120} $ Protein of HCV Interacts with E7 Antigen of Human Papilloma Virus Type 18 | |
| Etiévant | The third component of complement. Chemistry and biology: Lambris, JD Current topics in microbiology and immunology, vol. 153. 1 vol.(26× 17 cm), 251 pages, 38 fig., 18 tables. Springer-Verlag, Berlin, Heidelberg, 1989 | |
| Xiao-Guo et al. | Research for recombinant epitope antigens of hepatitis Cvirus | |
| TH12086B (th) | สารที่ใช้วินิจฉัย hcv ชนิดปรับปรุง |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |